Complement C3 – targeted intervention as a novel host modulation therapy in periodontal diseases
Gingivitis and periodontitis are prevalent inflammatory diseases of the periodontal tissues. Current treatments are often ineffective or do not prevent disease recurrence. Uncontrolled complement activation and resulting chronic gingival inflammation is a hallmark of periodontal diseases. We have developed a novel safe and efficacious treatment by using the complement 3-targeted therapeutic, AMY-101, locally administered in patients with periodontal inflammation.